Open Access Research article

Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

Andrew Stein1*, Wenping Wang2, Alison A Carter3, Ovidiu Chiparus4, Norbert Hollaender5, Hyewon Kim6, Robert J Motzer7 and Celine Sarr8

Author Affiliations

1 Modeling & Simulation, Novartis Institutes for Biomedical Research, 45 Sidney St, Cambridge, MA, USA

2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

5 Novartis Pharma AG, Basel, Switzerland

6 Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA

7 Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

8 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

For all author emails, please log on.

BMC Cancer 2012, 12:311  doi:10.1186/1471-2407-12-311

Published: 23 July 2012

Additional files

Additional 1:

Fig. A1 Tumor growth in a small number of RECORD-1 patients was not well described by model 2 with E5 ≠ E10. These included: i-iv) resistant patients (n = 4); (v) 5 mg of everolimus had an equivalent effect to 10 mg of everolimus (n = 1); (vi) tumor shrinkage during placebo treatment, but progression due to nontarget lesions (n = 1); (vii) tumor growth at 10 mg everolimus is faster than tumor growth at 5 mg everolimus (n = 1). E5, treatment effect of everolimus 5 mg daily; E10, treatment effect of everolimus 10 mg daily; SLD, sum of the longest tumor diameters.

Format: DOC Size: 246KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data